MaxCyte to acquire Akron BioProducts in cell-therapy materials expansion
MaxCyte agreed to buy Akron BioProducts for cash, stock and deferred payments, adding a bioprocessing materials business to its cell-therapy platform.
MaxCyte (Nasdaq: MXCT) said on Nov. 10 that it agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The transaction would expand MaxCyte’s offerings around cell and gene therapy manufacturing.
Cash, shares and deferred consideration
Under the securities purchase agreement, MaxCyte will pay $105 million in cash at closing, issue 20,639,733 shares of common stock and make $20 million in guaranteed deferred cash payments. The deferred amounts are scheduled as two $10 million payments in 2028 and 2029.
The closing is expected before the end of 2026. It remains subject to customary conditions, including the expiration or termination of the applicable U.S. antitrust waiting period and Nasdaq approval of the stock consideration. The agreement is not subject to a financing condition or MaxCyte stockholder approval, according to the company’s Form 8-K.
What changes for MaxCyte
MaxCyte provides cell-engineering technology used by biopharmaceutical companies, while Akron BioProducts supplies materials and services used in bioprocessing. The proposed combination would broaden MaxCyte’s commercial offering, but the filing does not provide a forecast of incremental revenue or earnings from Akron.
The stock consideration will be subject to a six-month lock-up after closing. MaxCyte said the transaction is targeted to close within the year, but completion remains conditional and the agreement includes customary termination rights.
Sources
This story describes figures the company has published. It is for information only and is not investment advice or a recommendation to buy, sell or hold any security. Check the original filings before relying on any figure. Stoqly is not affiliated with the SEC or Maxcyte, Inc..
